Viela Bio
| General Information | |
| Business: |
We are a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, which we collectively refer to as autoimmune diseases. Our approach seeks to redefine the treatment of autoimmune diseases by focusing on critical biological pathways shared across multiple diseases. |
| Industry: | PHARMACEUTICAL PREPARATIONS |
| Employees: | 80 |
| Founded: | 2017 |
| Contact Information | |
| Address | One MedImmune Way, First Floor, Area Two, Gaithersburg, MD 20878, US |
| Phone Number | (240) 558-0038 |
| Web Address | http://www.vielabio.com |
| View Prospectus: | Viela Bio |
| Financial Information | |
| Market Cap | $943.67mil |
| Revenues | $20.0 mil (last 12 months) |
| Net Income | $-57.2 mil (last 12 months) |
| IPO Profile | |
| Symbol | VIE |
| Exchange | NASDAQ |
| Shares (millions): | 7.9 |
| Price range | $19.00 - $19.00 |
| Est. $ Volume | $150.1 mil |
| Manager / Joint Managers | Goldman Sachs/ Morgan Stanley/ Cowen and Company |
| CO-Managers | Guggenheim Securities |
| Expected To Trade: | 10/3/2019 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |